StreetInsider.com News Articles

Form 144 Enliven Therapeutics, Filed by: Collins Helen Louise

Fri, 17 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260717/26784781.html

Form 144 Enliven Therapeutics, Filed by: Collins Helen Louise

Fri, 17 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260717/26784781.html

Enliven Therapeutics (ELVN) PT Raised to $65 at H.C. Wainwright

Thu, 09 Jul 2026 06:47:50 -0400

(Updated - July 9, 2026 6:47 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $65.00 (from $56.00) while maintaining a Buy rating.

The analyst commented: "During the EHA meeting in Stockholm this summer, Enliven presented updated results from the Phase 1 ENABLE trial, which is evaluating ELVN-001 in heavily pretreated chronic myelogenous leukemia (CML) patients. As seen in the oral presentation, treatment with ELVN-001 80mg (n=49; 3 median prior Rx [59% >3 prior TKIs; 37% >4 prior TKIs]; 55% prior asciminib; 27% prior ponatinib; 21% >10% baseline BCR::ABL1) resulted in a 61% (17/28)

Enliven Therapeutics (ELVN) PT Raised to $65 at H.C. Wainwright

Thu, 09 Jul 2026 06:47:50 -0400

(Updated - July 9, 2026 6:47 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $65.00 (from $56.00) while maintaining a Buy rating.

Form 4 Enliven Therapeutics, For: Jul 06 Filed by: Kunkel Lori Anne

Wed, 08 Jul 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260708/26748341.html

Form 4 Enliven Therapeutics, For: Jul 06 Filed by: Kunkel Lori Anne

Wed, 08 Jul 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260708/26748341.html

Enliven Therapeutics (ELVN) PT Raised to $80 at Stifel

Wed, 01 Jul 2026 08:23:11 -0400

Stifel analyst Dara Azar raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $80.00 (from $60.00) while maintaining a Buy rating.

Enliven Therapeutics (ELVN) PT Raised to $70 at Jones Trading

Mon, 29 Jun 2026 07:02:16 -0400

Jones Trading analyst Boris Peaker raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $70.00 (from $45.00) while maintaining a Buy rating.

The analyst comments "What's new: On back of the positive Ph I update shown at EHA 2026 (see prior note HERE), we are upgrading our PT to $70 from $45 and reiterating our BUY rating. Model changes: We have changed our ELVN model to reflect the company's decision to pursue the 1L/2L+ CML settings in two Ph III trial. Briefly, approx. 3:100,000 patients in the U.S. will be diagnosed with CML with a prevalence of ~105,000 patients in

Enliven Therapeutics (ELVN) PT Raised to $70 at Jones Trading

Mon, 29 Jun 2026 07:02:16 -0400

Jones Trading analyst Boris Peaker raised the price target on Enliven Therapeutics (NASDAQ: ELVN) to $70.00 (from $45.00) while maintaining a Buy rating.

Form 4 Enliven Therapeutics, For: Jun 22 Filed by: OrbiMed Genesis GP LLC

Wed, 24 Jun 2026 19:20:00 -0400

si-local-file:///var/storage/secattach/20260624/26686813.html

Form 4 Enliven Therapeutics, For: Jun 22 Filed by: OrbiMed Genesis GP LLC

Wed, 24 Jun 2026 19:20:00 -0400

si-local-file:///var/storage/secattach/20260624/26686813.html

Form SCHEDULE 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC

Wed, 24 Jun 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260624/26686808.html

Form SCHEDULE 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC

Wed, 24 Jun 2026 19:16:00 -0400

si-local-file:///var/storage/secattach/20260624/26686808.html

Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC

Mon, 22 Jun 2026 20:13:00 -0400

si-local-file:///var/storage/secattach/20260622/26674562.html

Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC

Mon, 22 Jun 2026 20:13:00 -0400

si-local-file:///var/storage/secattach/20260622/26674562.html

Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC

Mon, 22 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260622/26674557.html

Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC

Mon, 22 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260622/26674557.html

Form 144 Enliven Therapeutics, Filed by: ORBIMED CAPITAL LLC

Mon, 22 Jun 2026 20:08:00 -0400

si-local-file:///var/storage/secattach/20260622/26674556.html

Form 144 Enliven Therapeutics, Filed by: ORBIMED CAPITAL LLC

Mon, 22 Jun 2026 20:08:00 -0400

si-local-file:///var/storage/secattach/20260622/26674556.html

Form 4 Enliven Therapeutics, For: Jun 17 Filed by: Hohl Benjamin

Mon, 22 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260622/26674080.html

Form 4 Enliven Therapeutics, For: Jun 17 Filed by: Hohl Benjamin

Mon, 22 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260622/26674080.html

Form 4 Enliven Therapeutics, For: Jun 17 Filed by: Collins Helen Louise

Mon, 22 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260622/26674069.html

Form 4 Enliven Therapeutics, For: Jun 17 Filed by: Collins Helen Louise

Mon, 22 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260622/26674069.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc

Mon, 22 Jun 2026 09:29:00 -0400

si-local-file:///var/storage/secattach/20260622/26670991.html

Form SCHEDULE 13G/A Enliven Therapeutics, Filed by: Polar Capital Holdings Plc

Mon, 22 Jun 2026 09:29:00 -0400

si-local-file:///var/storage/secattach/20260622/26670991.html